DV
Dividend Vision

COAG — Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. (COAG)

Total return is 205.2% over the past 0.3 years, 196.9 points ahead of SPY at 8.3%.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing bispecific and monovalent antibodies to treat blood coagulation disorders, including therapies in Phase 1/2 and Phase 2 clinical development for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand disease. The company does not currently distribute dividends. As a pre-revenue clinical-stage biotech company, it appeals primarily to investors with risk tolerance for early-stage therapeutic development and no current need for income.

COAG key facts

Asset type
Stock
Asset class
Equity
Inception date
04/30/2026
Distribution frequency
None
Last close
$54.94
Market cap
$2,565,995,008
Average volume
101167.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.83